Several studies have shown adherence to guidelines for early stage BC diverged between countries7 and tumour characteristics; triple negative breast cancer7,8 and hormone receptors-negative HER2 positive9 being the subgroups with lower adherence. This evidence concerns the gene ERBB2 and breast cancer.